Skip to main content

Advertisement

Table 1 Summary of study characteristics of the included studies

From: A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)

Observational Studies Sample Size
Author Year Study Design Dx Cytokine Origin Cytokine Analysis Country CFS/ME HC
Fletcher, et al. [20] 2009 Case Control Fukuda Serum ELISA U.S.A. 40 59
Hardcastle, et al. [21] 2015 Case Control Fukuda Serum MBAA Australia 41 22
Hornig, et al. [22] 2016 Case Control Fukuda and CCC CSF MBAA U.S.A. 32 19
Kennedy, et al. [23] 2004 Case Control Fukuda Serum ELISA United Kingdom 47 34
Landi, et al. [24] 2016 Case Control Fukuda and/or CCC Serum ELISA U.S.A. 100 79
Montoya J, et al. [25] 2017 Case Control Fukuda Serum MBAA U.S.A. 186 388
Nakamura, et al. [26] 2010 Case Control Fukuda Serum MBAA U.S.A. 11 24
Nas K, et al. [27] 2011 Case Control ICC Serum MBAA Turkey 25 20
Natelson, et al. [28] 2005 Case Control Fukuda CSF MBAA U.S.A. 44 13
Neu D, et al. [29] 2014 Case Control Fukuda Serum MBAA Belgium 13 11
Peterson, et al. [30] 2015 Case Control Fukuda CSF MBAA U.S.A. 18 5
Repka-Ramirez, et al. [31] 2002 Case Control Fukuda Nasal Lavage ELISA U.S.A. 95 89
Russell, et al. [32] 2016 Case Control ICC Serum ELISA U.S.A. 50 69
Suhadolnik, et al. [33] 2004 Case Control Fukuda Serum ELISA U.S.A. 66 62
Tomoda et al. [34] 2005 Case Control Fukuda Serum ELISA Japan 15 23
  1. Dx CFS/ME diagnostic criteria used, HC healthy control(s), ELISA enzyme-linked immunosorbent assay, MBAA multiplex bead array assay, CCC Canadian Consensus Criteria, ICC International Consensus Criteria, CSF cerebrospinal fluid
  2. This table is a summary of the characteristics of the included studies